Form D · Pharmaceuticals
Nutrivert Inc.
Atlanta, GA · CIK 0001970591
Offering snapshot reported Apr 29, 2026 · SEC filing
- Reported sold
- $2.37M Offering amount: $6M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 10, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 29, 2026 | Initial | $2,374,992 | No comparison | 2 | SEC filing |
| Mar 23, 2023 | Initial | $1,500,274 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-582294
Source: Form D, filed Apr 29, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bernhard Kaltenboeck | Director, Executive |
| Troy Merry | Director |
| Horace Nalle | Director, Executive |
| Jonathon Quigley | Director |
| Peter Selover | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2525 Peachtree Road Ne #27
Atlanta, GA, 30305
Phone: (404) 680-1486
Atlanta, GA, 30305
Phone: (404) 680-1486